Lin Wei-Chen, Wu Tsung-Jui, Wang Chih-Hsien, Hsieh Yi-Jen, Hsu Bang-Gee
Division of Nephrology, Department of Internal Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan.
Division of Nephrology, Department of Medicine, Hualien Armed Forces General Hospital, Hualien 971051, Taiwan.
J Pers Med. 2023 Mar 4;13(3):470. doi: 10.3390/jpm13030470.
Cardiovascular diseases (CVDs) remain a significant cause of death in hemodialysis (HD) patients. To explore their associations, we examine the role of soluble urokinase-type plasminogen activator receptor (suPAR) in arterial stiffness in chronic HD patients. From June to August 2020, we recruited 135 chronic HD patients. The arterial stiffness group included patients with a carotid-femoral pulse-wave velocity (cfPWV) of >10 m/s. Fifty-five HD patients (40.7%) were in the arterial stiffness group. They had a higher prevalence of diabetes ( = 0.001) and hypertension ( = 0.039), were older ( = 0.007) and had higher aortic systolic blood pressure ( = 0.034), brachial systolic blood pressure ( = 0.025), glucose ( = 0.019), C-reactive protein ( = 0.039), and AIx75 ( = 0.003) and suPAR ( < 0.001) levels than the control group. After we performed multivariable logistic regression analysis, except age and glucose, serum suPAR (odds ratio [OR]: 2.05; 95% confidence interval [CI]: 1.48-2.70, < 0.001) was independently associated with arterial stiffness in chronic HD patients. In the multivariable linear regression analysis, suPAR positively correlated with cfPWV (β = 0.475, < 0.001) and could serve as a biomarker for arterial stiffness development in patients undergoing HD.
心血管疾病（CVDs）仍然是血液透析（HD）患者死亡的重要原因。为了探究它们之间的关联，我们研究了可溶性尿激酶型纤溶酶原激活物受体（suPAR）在慢性HD患者动脉僵硬度中的作用。2020年6月至8月，我们招募了135例慢性HD患者。动脉僵硬度组包括颈股脉搏波速度（cfPWV）>10 m/s的患者。55例HD患者（40.7%）在动脉僵硬度组。他们患糖尿病（P = 0.001）和高血压（P = 0.039）的患病率更高，年龄更大（P = 0.007），主动脉收缩压（P = 0.034）、肱动脉收缩压（P = 0.025）、血糖（P = 0.019）、C反应蛋白（P = 0.039）、AIx75（P = 0.003）和suPAR（P < 0.001）水平均高于对照组。在进行多变量逻辑回归分析后，除年龄和血糖外，血清suPAR（比值比[OR]：2.05；95%置信区间[CI]：1.48 - 2.70，P < 0.001）与慢性HD患者的动脉僵硬度独立相关。在多变量线性回归分析中，suPAR与cfPWV呈正相关（β = 0.475，P < 0.001），可作为HD患者动脉僵硬度发展的生物标志物。
